journal
MENU ▼
Read by QxMD icon Read
search

Pharmacopsychiatry

journal
https://www.readbyqxmd.com/read/28926859/editorial-to-consensus-guidelines-for-therapeutic-drug-monitoring-in-neuropsychopharmacology
#1
Gerhard Gründer
No abstract text is available yet for this article.
September 19, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28922669/a-critical-commentary-on-the-2017-agnp-consensus-guidelines-for-therapeutic-drug-monitoring-in-neuropsychopharmacology
#2
Jose de Leon
In 2004, 2011, and 2017, the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), a group of German-speaking psychiatric researchers and psychiatrists, published successive versions of therapeutic drug monitoring (TDM) expert group consensus guidelines. The 2017 version has as a major strength its encyclopedic nature, including 1358 references. The guideline has 3 major sections: 1) theoretical aspects of TDM, 2) drug concentration levels in blood to guide neuropsychopharmacotherapy, and 3) practical aspects of TDM in psychiatry and neurology...
September 18, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28910830/consensus-guidelines-for-therapeutic-drug-monitoring-in-neuropsychopharmacology-update-2017
#3
C Hiemke, N Bergemann, H W Clement, A Conca, J Deckert, K Domschke, G Eckermann, K Egberts, M Gerlach, C Greiner, G Gründer, E Haen, U Havemann-Reinecke, G Hefner, R Helmer, G Janssen, E Jaquenoud, G Laux, T Messer, R Mössner, M J Müller, M Paulzen, B Pfuhlmann, P Riederer, A Saria, B Schoppek, G Schoretsanitis, M Schwarz, M Silva Gracia, B Stegmann, W Steimer, J C Stingl, M Uhr, S Ulrich, S Unterecker, R Waschgler, G Zernig, G Zurek, P Baumann
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities...
September 14, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28859206/beta-blockers-and-evidence-based-guidelines-for-the-pharmacological-management-of-acute-methamphetamine-related-disorders-and-toxicity
#4
John R Richards
No abstract text is available yet for this article.
August 31, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28850959/epileptic-seizures-under-antidepressive-drug-treatment-systematic-review
#5
Tilman Steinert, Walter Fröscher
Objective This paper is a systematic review on seizures under treatment with substances licensed for major depression. Method Systematic review protocol is available in PROSPERO registration number CRD42016034010. Twenty-five substances were selected according to frequencies of prescriptions and publications. A PubMed search was conducted with "substance name" and "seizure." Results A total of 2291 articles were screened, out of which 164 fulfilled inclusion criteria. Data synthesis was possible only to a limited extent due to heterogeneity of included patients, observation periods, methods, and outcomes...
August 29, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28810270/the-personal-antipsychotic-choice-index
#6
Floor van Dijk, Iris de Wit, Matthijs Blankers, Iris Sommer, Lieuwe de Haan
Introduction We present an online decision aid to involve patients with a psychotic disorder in shared decision-making concerning the selection of antipsychotic medication. Method Patients selected effectiveness and adverse effects criteria from the Subject's Response to Antipsychotics-34 questionnaire. Numerical data from meta-analyses, clinical trial data, receptor affinities and expert opinions were used to rank antipsychotics on each criterion. When using the the tool, patients indicate on a 5-point Likert scale how they value each (adverse) effect...
August 15, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28768341/prediction-model-of-serum-lithium-concentrations
#7
Kazunari Yoshida, Hiroyuki Uchida, Takefumi Suzuki, Masahiro Watanabe, Nariyasu Yoshino, Hitoshi Houchi, Masaru Mimura, Noriyasu Fukuoka
Introduction Therapeutic drug monitoring is necessary for lithium, but clinical application of several prediction strategies is still limited because of insufficient predictive accuracy. We herein proposed a suitable model, using creatinine clearance (CLcr)-based lithium clearance (Li-CL). Methods Patients receiving lithium provided the following information: serum lithium and creatinine concentrations, time of blood draw, dosing regimen, concomitant medications, and demographics. Li-CL was calculated as a daily dose per trough concentration for each subject, and the mean of Li-CL/CLcr was used to estimate Li-CL for another 30 subjects...
August 2, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28718181/erythropoietin-for-cognitive-deficits-associated-with-schizophrenia-bipolar-disorder-and-major-depression-a-systematic-review
#8
Xian-Bin Li, Wei Zheng, Yu-Ping Ning, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Chuan-Yue Wang, Yu-Tao Xiang
Introduction The purpose of this study is to systematically review the efficacy and safety of adjunctive erythropoietin (EPO) in treating cognitive deficits associated with schizophrenia, bipolar disorder, and major depression based on randomized controlled trials (RCTs). Methods Two evaluators independently and systematically searched and selected studies, extracted data, and conducted quality assessment. Results Four RCTs with 144 patients (71 in the EPO group and 73 in the placebo group) met the study entry criteria...
July 17, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28675911/patients-knowledge-about-prescribed-antipsychotics-and-medication-adherence-in-schizophrenia-a-cross-sectional-survey
#9
Nobuhiro Nagai, Hideaki Tani, Takefumi Suzuki, Saeko Ikai, Philip Gerretsen, Masaru Mimura, Hiroyuki Uchida
Introduction Data on the knowledge about antipsychotic medications prescribed in patients with schizophrenia are very limited. Moreover, it remains unclear how patients' knowledge about prescribed antipsychotics affects medication adherence. Methods ighty-one Japanese outpatients with schizophrenia according to the International Classification of Diseases, 10th edition, were included. Patients' knowledge of the primary antipsychotics prescribed to them in terms of therapeutic effects, type, and implicated neurotransmitters was assessed with a multiple-choice questionnaire developed for this study...
July 4, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28905986/gearing-up-for-the-pearl-anniversary-agnp-set-to-hold-its-30th-meeting-in-munich-october-4%C3%A2-6-2017-overview-and-abstracts
#10
Golo Kronenberg, Jens Wiltfang, Johannes Thome
No abstract text is available yet for this article.
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28898894/editorial-to-driving-ability-and-psychotropic-drugs
#11
Gerd Laux, Michael Bauer
No abstract text is available yet for this article.
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28718182/driving-under-the-influence-of-antidepressants-a-systematic-review-and-update-of-the-evidence-of-experimental-and-controlled-clinical-studies
#12
Alexander Brunnauer, Gerd Laux
Introduction This review provides an update of experimental and clinical studies on the effects of antidepressants on driving performance. Methods A systematic literature search on the PubMed database (1980-2016) was performed. Results Twenty-eight studies could be included in this review, whereas only 5 studies investigated driving performance under antidepressants in patients. Most tri- and tetracyclics have acute deleterious effects on driving performance that, except for mianserin, attenuate after subchronic use...
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28675912/influence-of-long-term-benzodiazepine-use-on-neurocognitive-skills-related-to-driving-performance-in-patient-populations-a-review
#13
Nick N J J M van der Sluiszen, Annemiek Vermeeren, Stefan Jongen, Frederick Vinckenbosch, Johannes G Ramaekers
Acute benzodiazepine intoxication produces severe impairment of neurocognitive skills related to driving. It is less clear whether such impairments also occur in patients who use benzodiazepines chronically. The current review evaluated neurocognitive skills of long-term benzodiazepine users and addressed 2 major questions: do long-term users develop tolerance for the impairing effects of benzodiazepines on neurocognitive performance, and if so, does tolerance warrant a change in driver fitness classification systems that currently deem users of benzodiazepines unfit to drive? Neurocognitive impairments were reported in patients who on average used benzodiazepines for 5-15 years...
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28672405/driving-performance-of-depressed-patients-who-are-untreated-or-receive-long-term-antidepressant-ssri-snri-treatment
#14
Nick N J J M van der Sluiszen, Marleen Wingen, Annemiek Vermeeren, Frederick Vinckenbosch, Stefan Jongen, Johannes G Ramaekers
Introduction Depression is a mental disorder likely to affect everyday functions. The present study aimed to assess actual driving performance of depressed patients who were without specific antidepressant treatment or received long-term antidepressant treatment. Methods A standardized on-the-road driving test was used to assess standard deviation of lateral position (SDLP) in 3 patient groups receiving either no antidepressant treatment (with or without benzodiazepine medication) or treatment with selective serotonin/noradrenalin reuptake inhibitors for a period of 6-52 weeks...
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28641332/executive-dysfunctions-predict-self-restricted-driving-habits-in-elderly-people-with-or-without-alzheimer-s-dementia
#15
Ilsemarie Kurzthaler, Georg Kemmler, Michaela Defrancesco, Bernadette Moser, Wolfgang W Fleischhacker, Elisabeth M Weiss
Introduction The purpose of this study was to elucidate the impact of specific cognitive functions on self-restricted driving habits in healthy elderly drivers and patients suffering from mild cognitive impairment (MCI) and Alzheimer's dementia (AD). Method Our study population included 35 cognitively healthy controls, 10 MCI patients, and 16 patients with AD. All participants completed a neuropsychological examination and a self-reported questionnaire assessing driving habits and patterns. Results In challenging driving conditions, patients with MCI or AD showed significantly more driving self-restriction than healthy subjects (effect size d=1...
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28521367/driving-problems-in-the-elderly-and-cognitively-impaired
#16
Robert Haussmann, Maria Buthut, Markus Donix
Driving ability in the elderly and cognitively impaired is of growing demographic relevance. Driving represents a complex task for which multiple central resources are needed. In mild cognitive impairment and dementia, we need to closely monitor driving ability, as it gets irrecoverably lost in the course of the disease. In normal aging, people are often able to self-regulate driving behavior with respect to their medical conditions. Some studies demonstrated that older drivers perform well compared with younger drivers...
September 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28511206/antipsychotic-treatment-of-22q11-2-deletion-syndrome-related-psychoses
#17
Elias Angelopoulos, Christos Theleritis, Marina Economou, Korina Georgatou, Charalambos C Papageorgiou, Eleftheria Tsaltas
In the recent study by Verhoeven and Egger, 2015 and the recent letter to the editor by Boot et al. 2015 an emphasis is given to the best possible pharmacological treatment of 22q11-2 Deletion-Syndrome related psychoses. We would like to present the case of a 23-year old Cypriot patient with 22q11.2 deletion syndrome who fulfilled criteria for treatment resistant schizophrenia (TRS). He was sequentially treated with aripiprazole, risperidone, olanzapine, haloperidol and a combination treatment with olanzapine and haloperidol...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28505669/add-on-antidepressants-in-the-naturalistic-treatment-of-schizophrenia-spectrum-disorder-when-who-and-how
#18
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Ilja Spellmann, Richard Musil, Hans-Jürgen Möller, Michael Riedel
The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28346959/mirtazapine-induces-nightmares-in-depressed-patients
#19
Jens-Armin Buschkamp, Corinna Frohn, Georg Juckel
No abstract text is available yet for this article.
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27701683/crocus-sativus-l-versus-citalopram-in-the-treatment-of-major-depressive-disorder-with-anxious-distress-a-double-blind-controlled-clinical-trial
#20
A Ghajar, S M Neishabouri, N Velayati, L Jahangard, N Matinnia, M Haghighi, A Ghaleiha, M Afarideh, S Salimi, A Meysamie, S Akhondzadeh
Introduction: Saffron (Crocus sativus L.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. Methods: 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. Results: 60 participants finished the study...
July 2017: Pharmacopsychiatry
journal
journal
28729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"